Table 2

Baseline characteristics of the patients with complete and incomplete follow-up data

VariableFollow-up data available (n = 3,775)Follow-up data incomplete (n = 229)P
Recruiting event0.15
 CABG11.1 (419/3,775)12.2 (28/229)
 PCI55.2 (2,083/3,775)48.9 (112/229)
 AMI23.2 (877/3,775)29.3 (67/229)
 Ischemia10.5 (396/3,775)9.6 (22/229)
Age at interview (years)63.8 (9.69)60.8 (11.0)<0.0001
Female sex23.6 (891/3,775)22.3 (51/229)0.69
Time since hospital discharge (years)1.5 (0.69)1.5 (0.73)0.52
Low educational level16.8 (632/3,750)20.7 (47/227)0.15
Current smoking15.3 (578/3,775)22.3 (51/229)0.007
Regular physical activity45.0 (1,563/3,471)29.5 (62/210)<0.0001
BMI (kg/m2)28.6 (4.3)28.2 (4.6)0.10
Obesity33.1 (1,249/3,771)29.0 (66/228)0.22
Central obesity54.6 (2,041/3,737)56.7 (122/215)0.57
Blood pressure (mmHg)
 Systolic132.5 (18.8)128.4 (17.5)0.002
 Diastolic78.3 (10.8)78.9 (10.8)0.38
Cholesterol (mmol/L)
 Total4.5 (1.09)4.8 (1.01)0.15
 LDL2.6 (0.91)2.7 (0.89)0.04
Plasma glucose
 Fasting (mmol/L)5.7 (0.42)5.8 (0.46)0.003
 2h-PG (mmol/L)6.4 (0.90)6.3 (0.97)0.58
HbA1c DCCT (%)7.9 (2.71)8.1 (2.59)0.22
HADS Anxiety score5.2 (3.81)6.3 (4.31)0.0008
HADS Depression score4.4 (3.53)5.0 (3.82)0.04
Pharmacological treatment
 Antiplatelet93.2 (3,504/3,761)94.7 (215/227)0.42
 Lipid lowering85.9 (3,231/3,761)83.2 (189/227)0.28
 β-Blockers81.9 (3,080/3,761)80.2 (182/227)0.54
 ACE inhibitors58.8 (2,212/3,761)54.2 (123/227)0.19
 ARB15.9 (599/3,761)16.3 (37/227)0.85
 ACE inhibitors or ARB74.2 (2,790/3,761)69.2 (157/227)0.10
 Diuretics24.5 (920/3,761)26.4 (60/227)0.52
  • The data are presented as proportions (% = n/N of observations × 100) or as mean (SD).

  • ARB, angiotensin receptor blocker.